Kolon Life Science and Mundipharma Korea said Invossa-K, a knee osteoarthritis generic therapy, has passed reviews of drug committees at 60 general hospitals across the nation on Monday along with the first prescription at Seoul National University Hospital.
Since the release in November, Invossa has marked more than 1,000 procedures in seven months.
“Invossa-K has landed at major general hospitals nationwide. We can feel that physicians and patients are very interested in Invossa-K,” an official at Kolon Life Science said. “As many international orthopedic societies recognize it as gene therapy, we hope that more general hospitals will prescribe it.”
Invossa-K won approval from the Ministry of Food and Safety in July last year and began to sell in November. Invossa’s phase-3 study results have been recently announced at prestigious international orthopedic and joint-related conferences, including the American Academy of Orthopaedic Surgeons (AAOS), International Cartilage Regeneration and Joint Preservation (ICRS), and Osteoarthritis Research Society International (OARSI).